Jun 25 |
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
|
Jun 14 |
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
|
May 30 |
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
|
May 16 |
Cyclo Therapeutics reports Q1 results
|
May 16 |
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
Apr 10 |
Pleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics Stock
|
Mar 18 |
Cyclo Therapeutics reports FY results
|
Mar 18 |
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
|
Mar 14 |
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
|
Mar 13 |
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
|